ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0984

Factors Associated with 5-year Mortality in Patients with Rheumatoid Arthritis Initiating Their First Biological or Target Synthetic DMARDs: A Nationwide, Population-based Cohort Study of 12,612 Patients
Abstract Number: 0985

Assessing the Value of Comorbidity Clusters in Predicting Clinical Outcomes in Rheumatoid Arthritis: A Machine Learning Approach Using a Very Large US Registry
Abstract Number: 0986

Medication Use Patterns and Factors Associated with Abnormal Pregnancy Outcomes in Patients with Rheumatoid Arthritis in Korea
Abstract Number: 0987

Risk Factors and Predictors of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
Abstract Number: 0988

Elderly Patients’ Discontinuation of Biologic DMARDs in Patients with Rheumatic Diseases: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
Abstract Number: 0989

Rheumatoid Arthritis and Risk of Migraine: A Population-based Nationally Representative Cohort
Abstract Number: 0990

Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry
Abstract Number: 0991

Trends in Arthroplasty Utilization for Inflammatory Arthritis Including Rheumatoid Arthritis and Spondyloarthritis in China: Analysis of a Large National Database
Abstract Number: 0992

Association Between Metabolic Syndrome and the Presence of Enthesophytes on Musculoskeletal Ultrasound Compared to Joint X-ray
Abstract Number: 0993

Successful Implementation of a New Patient Video Triage Program
Abstract Number: 0994

Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias
Abstract Number: 0995

Rheumatoid Arthritis Early Diagnostic Clinic: A Web-based Referral Tool Serving Ethnic Minority Patients
Abstract Number: 0996

Will Patients Engage with Digital Technologies as Part of Routine Healthcare?
Abstract Number: 0997

Impact of Depression on Healthcare Utilization in Members with Underlying Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus
Abstract Number: 0998

Barriers and Facilitators for Osteoporosis and Sarcopenia Care for Persons Living with HIV in Peru: HIV Physician and Coordinator Perspectives

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].